Affordability Of Essential Medicines Research Articles

Unfettered Consumer Access to Affordable Therapies in the Post-TRIPS Era: A Dead-End Journey for Patients? Kenya and India Case Studies

Increasing access to essential medicines has become an international priority, given the rapid spread of intractable diseases such as HIV/AIDS, tuberculosis and malaria. It follows that the quests to improve the global quality of healthcare and achieve health equity present a challenge for many countries, especially those that have been hard hit by deadly pandemics and whose populations are also still without essential drugs. Consequently, many countries have stepped up efforts to remove the obstacles to the availability and affordability of essential medicines. The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) contains flexibilities that can be used as tools for enhancing access to cheap medicines and for controlling drug pricing. However, these flexibilities are not necessarily a panacea and cannot singly solve the problem of limited access to essential medicines. Put differently, cheaper medicines cannot reach the poor without the infrastructure to deliver them. For this to become a reality, commitment on the part of the member countries to adopt comprehensive and cooperative measures to tackle the burdensome barriers that limit access to critical medicines is needed. It is only then that the flexibilities in TRIPS can be optimized and a real difference made in the lives of poor patients across the developing world.

Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China

To investigate the availability of essential medicines and their prices in Hubei province. The survey assessed the prices and availability of essential medicines using the World Health Organization and Health Action International methodology. Data were collected from 18 public hospitals and 18 private pharmacies. At each facility the availability and prices of 39 innovator brand medicines and lowest-price generic equivalent medicines were collected. Medicine prices were compared with international reference prices to obtain a median price ratio (MPR). Daily incomes of low and average levels were used to assess the affordability of the medicines. Median availability in the public and private sectors was low (38.9% and 44.4% for lowest-price generics, respectively). The median MPRs of procurement prices for innovator brands and lowest-price generics in the public sector were 9.78 and 0.74 times the international reference prices; and the median MPRs of retail prices to patients for lowest-price generics in the public sector (1.04) were higher than those in the private sector (0.68). For most of the population, the medicine prices are affordable, but for those of low income they are not. The survey revealed low procurement prices but poor availability in the public sector. Various policy adjustments could increase the availability of essential medicines and reduce their prices for the low income population.

Affordability of essential medicines used for treating chronic diseases in Malaysia: An academic perspective

The aim of this study is to measure the affordability of drugs used in treating common chronic diseases. The study was conducted in the Universiti Sains Malaysia (USM) and in 5 private retail pharmacies. The study measured prescriptions contents of Universiti Sains Malaysia panel of clinics claim forms of patients for the year 2006. Affordability of medicines used was

Are Essential Medicines in Malaysia Accessible, Affordable and Available?

To assess the pharmaceutical sector to know whether people have access to essential medicines. The study was conducted in 20 public health clinics, five public district drug stores and 20 private retail pharmacies selected randomly in five different areas randomly selected (four states and a federal territory). The methodology used was adopted from the World Health Organization study protocol. The degree of attainment of the strategic pharmaceutical objectives of improved access is measured by a list of tested indicators. Access is measured in terms of the availability and affordability of essential medicines, especially to the poor and in the public sector. The first survey in the public health clinics and public district drug stores gathered information about current availability of essential medicines, prevalence of stock-outs and affordability of treatment (except drug stores). The second survey assessed affordability of treatment in public health clinics and private retail pharmacies. Availability, stock-out duration, percent of medicines dispensed, accessibility and affordability of key medicines. The average availability of key medicines in the public health clinics for the country was 95.4%. The average stock-out duration of key medicines was 6.5 days. However, average availability of key medicines in the public district drug stores was 89.2%; with an average stock-out duration of 32.4 days. Medicines prescribed were 100% dispensed to the patients. Average affordability for public health clinics was 1.5 weeks salary and for the private pharmacies, 3.7 weeks salary. The present pharmaceutical situation in the context of essential medicines list implementation reflected that the majority of the population in Malaysia had access to affordable essential medicines. If medicines need to be obtained from the private sector, they are hardly affordable. Although the average availability of essential medicines in Malaysia was high being more than 95.0%, in certain areas in Sabah availability was less than 80.0% and still a problem.